Fusion Pharmaceuticals Inc. Patent Applications Rejected
16 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2024-04-23: Application 18703993; Invention CLAUDIN 18.2-BINDING ANTIBODIES AND FRAGMENTS THEREOF; Applicant Fusion Pharmaceuticals Inc.; Status Abandoned -- Incomplete Application (Pre-examination).
- 2024-03-26: Application 18695724; Invention EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF; Applicant Fusion Pharmaceuticals Inc.; Status Abandoned -- Incomplete Application (Pre-examination).
- 2022-09-20: Application 17906857; Invention FGFR3-TARGETED RADIOIMMUNOCONJUGATES AND USES THEREOF; Applicant Fusion Pharmaceuticals Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2022-08-15: Application 17819911; Invention RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY; Applicant Fusion Pharmaceuticals Inc.; Status Abandoned -- Failure to Respond to an Office Action.
| Filed | Application | Invention | Applicant | Status | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|
| 2024-04-23 | 18703993 | CLAUDIN 18.2-BINDING ANTIBODIES AND FRAGMENTS THEREOF | Fusion Pharmaceuticals Inc. | Abandoned -- Incomplete Application (Pre-examination) | US20250002576A1 | Philipp Kuhn André Frenzel | Germany Germany | |
| 2024-03-26 | 18695724 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | Fusion Pharmaceuticals Inc. National Research Council of Canada | Abandoned -- Incomplete Application (Pre-examination) | US20240408249A1 | Natalie Grinshtein Julie Metcalf Ian R. Duffy William Leslie Turnbull Anne Marcil Maria Jaramillo Traian Sulea Maria Moreno Cunle Wu | United States Canada Canada Canada Canada Canada Canada Canada Canada | |
| 2022-09-20 | 17906857 | FGFR3-TARGETED RADIOIMMUNOCONJUGATES AND USES THEREOF | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20230201384A1 | Eric Steven Burak Marc Schwabish Natalie Grinshtein | Canada United States United States | BUTTICE, AUDREY L |
| 2022-08-15 | 17819911 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20230270895A1 | Eric Steven Burak Julie Metcalf Natalie Grinshtein Meiduo Hu John Fitzmaurice Valliant | Canada Canada United States Canada Canada | STOICA, ELLY GERALD |
| 2022-07-08 | 17791824 | SUSTAINED IMMUNOTHERAPY | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20230091468A1 | Eric Steven Burak Julie Metcalf Natalie Grinshtein Meiduo Hu John Fitznaurice valliant Sonal Patel | Canada Canada Canada Canada Canada Canada | WESTERBERG, NISSA M |
| 2022-05-18 | 17777850 | METHODS FOR TREATMENT OF CANCERS | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20240165280A1 | Eric S. Burak John R. Forbes Ryan W. Simms | Canada Canada Canada | VU, JAKE MINH |
| 2022-04-14 | 17769232 | METHODS OF TREATING CANCER | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20240139353A1 | Natalie Grinshtein Yaryna Storozhuk | Canada Canada | MEJIAS, SAMANTHA LEE |
| 2022-03-29 | 17707838 | ENDOSIALIN-BINDING ANTIBODY | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20220218836A1 | Stefano Iacobelli Annalisa Di Risio Enza Piccolo Gianluca Sala Emily Capone | Italy Italy Italy Italy Italy | XIAO, YAN |
| 2021-06-02 | 17337358 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20210290788A1 | Eric Steven Burak John Richard Forbes Meiduo Hu John Fitzmaurice Valliant | Canada Canada Canada Canada | VALLE, ERNESTO |
| 2021-06-02 | 17337357 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20210290789A1 | Eric Steven Burak Julie Metcalf Natalie Grinshtein Meiduo Hu John Fitzmaurice Valliant | Canada Canada Canada Canada Canada | VU, JAKE MINH |
| 2021-02-26 | 17272129 | MACROCYCLIC CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20210395281A1 | Stuart J. Mahoney Michael B. Johansen Matthew D. Moran Melissa Chassé Ryan W. Simms Eric S. Burak John F. Valliant | Canada Canada Canada Canada Canada Canada Canada | ADLAM, CHANTAL PETA-GAYE |
| 2020-10-05 | 17045320 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20210145971A1 | Mark T. Bilodeau Benoît Moreau Sudhakar Kadiyala Richard Wooster Brian H. White | United States United States United States United States United States | YOUNG, MICAH PAUL |
| 2020-04-27 | 16859006 | METHODS, COMPOSITIONS, AND KITS FOR TREATMENT OF CANCER | Fusion Pharmaceuticals, Inc. | Abandoned -- Failure to Respond to an Office Action | US20200308286A1 | Jocelyn Holash | United States | SAOUD, CHRISTINE J |
| 2020-02-28 | 16805508 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20200277387A1 | Graeme CURRIE | United States | LI, RUIXIANG |
| 2018-02-06 | 15890278 | METHODS, COMPOSITIONS, AND KITS FOR TREATMENT OF CANCER | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20180222983A1 | Jocelyn HOLASH | United States | SAOUD, CHRISTINE J |
| 2016-02-19 | 15048030 | FGFR3 AND PD1 INHIBITORY COMPOSITIONS AND ASSOCIATED METHODS OF USE FOR TREATING CANCER | Fusion Pharmaceuticals Inc. | Abandoned -- Failure to Respond to an Office Action | US20160243228A1 | Jocelyn HOLASH Stephen LAU | United States United States | SAOUD, CHRISTINE J |